Dynamic contrast-enhanced MRI using macromolecular contrast media for monitoring the response to isolated limb perfusion in experimental soft-tissue sarcomas

被引:19
作者
Preda, A
Wielopolski, PA
ten Hagen, TLM
van Vliet, M
Veenland, JF
Ambagtsheer, G
van Tiel, ST
Vogel, MW
Eggermont, AMM
Krestin, GP
van Dijke, CF
机构
[1] Univ Rotterdam Hosp, Ctr Med, Erasmus MC, Dept Radiol, NL-3015 GD Rotterdam, Netherlands
[2] Univ Rotterdam Hosp, Ctr Med, Erasmus MC, Dept Surg Oncol, NL-3015 GD Rotterdam, Netherlands
关键词
magnetic resonance imaging; isolated limb perfusion; tumor anglogenesis; microvascular permeability; soft-tissue sarcoma;
D O I
10.1007/s10334-004-0050-z
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The objective of this study was to evaluate the potential of dynamic contrast-enhanced MRI for quantitative characterization of tumor microvessels and to assess the microvascular changes in response to isolated limb perfusion with TNF-alpha and melphalan. Dynamic contrast-enhanced MRI was performed in an experimental cancer model, using a macromolecular contrast medium, albumin-(Gd-DTPA)(45)- Small fragments of BN 175, a soft-tissue sarcoma, were implanted in I I brown Norway (BN) rats. Animals were assigned randomly to a control (Haemaccel) or drug-treated group (TNF-alpha/melphalan). MRI was performed at baseline and 24 h after ILP. The transendothelial permeability (K-PS) and the fractional plasma volume (fPV) were estimated from the kinetic analysis of MR data using a two-compartment bi-directional model. K-PS and fPV decreased significantly in the drug-treated group compared to baseline (p < 0.05). In addition, K-PS post therapy was significantly lower (p < 0.05) in the drug-treated group than in the control group. There was no significant difference in fPV between the drug-treated and the control group after therapy Tumor microvascular changes in response to isolated limb perfusion can be determined after 24 h by dynamic contrast-enhanced MRI. The data obtained in this experimental model suggest possible applications in the clinical setting, using the appropriate MR contrast agents.
引用
收藏
页码:296 / 302
页数:7
相关论文
共 42 条
[41]  
WATANABE N, 1988, CANCER RES, V48, P2179
[42]  
White D, 1989, P SOC MAGN RES MED 8, P807